MAO-B-IN-62

MAO-B-IN-62 (compound 5) exhibits direct antioxidant activity by reducing ABIP-induced DCF oxidation by 65% in in vitro assays^[1].
MAO-B-IN-62 (5 μM; 30 min) significantly reduces Antimycin A-induced ROS production in LN229 glioblastoma cells and C20 microglial cells^[1].
MAO-B-IN-62 (100 μM; 1 h pretreatment + 24 h LPS stimulation) reduces LPS-induced pro-inflammatory cytokine release in enriched cultures of rat astrocytes^[1].
MAO-B-IN-62 (1-100 μM; 48 h or PPARγ assay duration) shows no cytotoxicity in HepG2, LN229 and C20 cell lines even at concentrations as high as 100 μM^[1].
MAO-B-IN-62 is a selective, reversible, competitive inhibitor of human recombinant MAO-B, with a K_i value of 1.8 μM; it inhibits MAO activity in rat astrocyte lysates with an IC₅₀ of 0.8 μM^[1].
MAO-B-IN-62 (100 μM; 4-20 h) is a selective full PPARγ agonist with an EC₅₀ of 14.6 μM, which exhibits persistent target binding and slow dissociation in transfected HepG2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.